Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Diosmin and Hesperidin Combination.
- Who it may be relevant to
- Registry conditions: Rheumatoid Arthritis. Basic parameters: 19 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Overview
Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis
Detailed description
Evaluation of the anti inflammatory and antioxidant effects of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis.
Clinical and functional assessment of disease activity.
Evaluation of hepatoprotective effect against methotrexate induced liver adverse events.
Interventions
- Drug Diosmin and Hesperidin Combination
Diosmin 450 mg and Hesperidin 50 mg Combination
Primary outcome measures
- Anti inflammatory Effect [Time frame: 3 months]
- Effect on disease activity [Time frame: 3 months]
Secondary outcome measures (1)
- Hepatoprotective Effect [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Patients with mild to moderate disease activity.
- Patient age must be more than 18 years.
Exclusion criteria
- Pregnant and lactating females.
- Patients with liver, renal impairment or any other inflammatory diseases.
- Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Alexandria university hospital — Alexandria
Identifiers
NCT: NCT05756179 · 0201734